The short version of Angiotensin IV analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
== Historical recipes == Gochujang ingredients reported in Jeungbo sallim gyeongje were 18 litres (19 US quarts) of powdered and sieved meju (fermented soybeans), 540 mL (18+1⁄2 US fl oz) of chili powder, and 1.8 L (1+7⁄8 U.S. qt) of glutinous rice flour, as well as soup soy sauce for adjusting the consistency. The gochujang recipe in Gyuhap chongseo, an 1809 cookbook, uses powdered meju made from 18 L (19 US qt) of soybeans and 3.6 L (3+3⁄4 US qt) of glutinous rice, then adding 900–1,260 mL (30+1⁄2–42+1⁄2 US fl oz) of chili powder and bap made from 3.6 L (3.8 US qt) of glutinous rice.
=== PG === The hydrostatic pressure within the glomerular capillaries is determined by the pressure difference between the fluid entering immediately from the afferent arteriole and leaving through the efferent arteriole. The pressure difference is approximated by the product of the total resistance of the respective arteriole and the flux of blood through it:
The initial product of that enzyme is the peracid of ureidoacrylic acid, to which it spontaneously converts. Pyrimidine oxygenase can also use thymine as a substrate and in that case its product is (Z)-2-methylureidoacrylic acid:
On April 17, 1848, a 42-year-old woman named Lu-shi was treated for hypertrophy in a Chinese hospital. She was treated by a missionary physician. On December 24, 1849, the left breast, measuring 67 cm (26 in) in circumference, and weighing 2.7 kg (6.0 lb), was removed in a procedure lasting three and a half minutes. The right breast was removed one month later. It measured 61 cm (24 in) in circumference and weighed 2.5 kg (5.5 lb). In 2005, a woman reported that her breasts grew at puberty from nothing to a C cup in one month. When she became pregnant for the first time, her breasts increased two cup sizes in a few days. Immediately after her first birth, her breasts grew three cup sizes. After her second child was born, her breasts increased six cup sizes. After her third childbirth, they grew ten cup sizes, and after her fourth child was born, they grew nine cup sizes. In this instance, the swelling abated about 10 days after childbirth, but her bra cup size remained E to a G for the next year. About one year postpartum, her breasts rapidly atrophied to AA cup size. One of the most severe cases of macromastia was reported from Ilorin in Nigeria. In 2007, Ganiyu Adebisi Rahman and his colleagues reported the case of a 26-year-old woman who presented with massive swelling of her breasts and bilateral axillary swellings of 6 years duration. Rahman led a team of surgeons in Ilorin to perform a total bilateral excision of the hypertrophied axillary breasts, and bilateral breast amputation with composite nipple-areola complex graft of the normally located breasts.
Sources: en.wikipedia.org
13 October A grenade was thrown in the Vi Thanh District Chieu Hoi center, killing three civilians and wounding 46. The VC kidnapped a Catholic priest and a lay assistant, from the church at Phu Hoi, Biên Hòa Province.
Projects Accomplished: Detectability of Corticosteroid in various Indian preparations: Effect on Endogenous steroid profile. Characteristics of IEF Patterns and SDS-PAGE Result of Indian EPO Biosimilars. Establishing Reference Range for Endogenous Steroids in Indian Sportspersons and to study the effect of ethnicity and steroid abuse on delta values of endogenous steroids. Analytical strategies in the development and utilization of mass spectrometric method for analysis of Stimulants & Narcotics. Effect of Ethnicity and Anabolic Steroid Abuse on Delta Value of Endogenous Steroids. Rapid Screening in Doping Analysis: Separation and Detection of Doping Agents be Liquid and Gas Chromatographic Mass Spectrometric Analysis. Current Projects: Detection of Synthetic glucocortico steroids, stimulants and anabolic steroids in Indian herbal drugs and supplements. Discrimination of biological and synthetic origin of anabolic steroids in human urine: Correlation between GCMSD & Isotope Ratio Mass Spectrometry. An Analytical approach for the Screening of Performance Enhancing Substances from various Dietary Supplements & to study their excretion profile using Chromatographic-Mass Spectrometric Technique. Development of analytical tools for the Detection and Identification of performance enhancing Peptides in Biological Specimen. An analytical approach for the Detection of Corticosteroids in Human and Horse Biological Specimen using Chromatographic and Mass Spectrometric Technique.
== Deterministic versus stochastic epidemic models == The deterministic models presented here are valid only in case of sufficiently large populations, and as such should be used cautiously. These models are only valid in the thermodynamic limit, where the population is effectively infinite. In stochastic models, the long-time endemic equilibrium derived above, does not hold, as there is a finite probability that the number of infected individuals drops below one in a system. In a true system then, the pathogen may not propagate, as no host will be infected. But, in deterministic mean-field models, the number of infected can take on real, namely, non-integer values of infected hosts, and the number of hosts in the model can be less than one, but more than zero, thereby allowing the pathogen in the model to propagate. The reliability of compartmental models is limited to compartmental applications. One of the possible extensions of mean-field models considers the spreading of epidemics on a network based on percolation theory concepts. Stochastic epidemic models have been studied on different networks and more recently applied to the COVID-19 pandemic.
Sources: en.wikipedia.org
β-Guanidinopropionic acid, also referred to as guanidinopropionic acid, beta-guanidinopropionic acid or β-GPA, is a dietary supplement. β-Guanidinopropionic acid, also known as Ompenaclid (RGX-202), is being investigated in colorectal cancer by Inspirna and Merck β-Guanidinopropionic acid is a white crystalline powder soluble in water (50 mg/ml-clear, colorless solution). Studies on animals (rats, monkeys, hamsters) show that acidic guanidine derivatives such as β-GPA can ameliorate hyperglycemia in animal models of noninsulin-dependent diabetes. Though the oral availability of β-GPA is well established, the basic uptake mechanism has not been studied yet.
Enhanced mobility – components are described as "familiar, performance-enhancing, eat-out-of-hand" foods that require little or no preparation by the soldier. The beverages are reconstituted (CamelBak compatible) and consumed right out of the pouch. No water is needed for food preparation, only for the beverage mix. The food takes the form of pocket sandwiches to be eaten by hand. Lightweight – when compared to three Meals, Ready-to-Eat, the FSR reduces the weight and volume of one day's subsistence by approximately 50%. Characteristics – has a minimum two-year shelf life at 80 °F (27 °C) and provides an average of 2,900 calories per day. The FSR has nine meals per shipping container consisting of three each of three different menus up through 2010. Since 2011 there are 9 different meal combinations per shipping container. Meals – Each pouch contains items for a breakfast, lunch, and a dinner, although there is no requirement to consume the items in any specific order.
Documented use of pennyroyal dates back to ancient Greek, Roman, and Medieval cultures. Its name – although of uncertain etymology – is associated with Latin pulex (flea), alluding to the manner in which it was used to drive away fleas when smeared on the body. Pennyroyal was commonly incorporated as a cooking herb by the Greeks and Romans. A large number of the recipes in the Roman cookbook of Apicius called for the use of pennyroyal, often along with such herbs as lovage, oregano and coriander. Although it was commonly used for cooking also in the Middle Ages, it gradually fell out of use as a culinary herb and is seldom used as such today. Records from Greek and Roman physicians and scholars contain information pertaining to pennyroyal's medicinal properties, as well as recipes used to prepare it. Pliny the Elder, in his encyclopedia Naturalis Historia (Natural History), described the plant as an emmenagogue, and that it also expelled a dead fetus. Galen only listed pennyroyal as an emmenagogue, as did Oribasius. Roman and Greek writers Quintus Serenus Sammonicus and Aspasia the Physician however both agreed that pennyroyal, when served in tepid water, was an effective abortive method. A medical text on gynecology attributed to Cleopatra (though it was actually written by a female Greek physician Metrodora) recommends the use of pennyroyal with wine to induce abortions. In regard to its contraceptive properties, it was referred to in a joking manner in Aristophanes' play Peace (421 BCE).
Noradrenergic and serotonergic nuclei in the ARAS are involved in the regulation of the REM sleep cycle and function as "REM-off" cells, with amphetamine's effect on norepinephrine and serotonin contributing to the suppression of REM sleep and a possible reduction of cataplexy at high doses. The American Academy of Sleep Medicine (AASM) 2021 clinical practice guideline conditionally recommends dextroamphetamine for the treatment of both type 1 and type 2 narcolepsy. Treatment with pharmaceutical amphetamines is generally less preferred relative to other stimulants (e.g., modafinil) and is considered a third-line treatment option. Medical reviews indicate that amphetamine is safe and effective for the treatment of narcolepsy. Amphetamine appears to be most effective at improving symptoms associated with hypersomnolence, with three reviews finding clinically significant reductions in daytime sleepiness in patients with narcolepsy. Additionally, these reviews suggest that amphetamine may dose-dependently improve cataplexy symptoms. However, the quality of evidence for these findings is low and is consequently reflected in the AASM's conditional recommendation for dextroamphetamine as a treatment option for narcolepsy.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.